Overview

Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary: - To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: - To assess the safety and tolerability of oxaliplatin - To assess time to progression and overall survival.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Oxaliplatin